Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced team with prior success in bringing important new drugs to market. We believe we have the resources, experience and drive to improve the lives of patients and build sustainable value for our shareholders.

Date Title   January 28, 2010 Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011 WILMINGTON, Del., Jan 28, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) today announced that it will redeem all of its outstanding 3½% Convertible Senior Notes due 2011 and all of its outstanding 3½% Convertible Subordinated Notes due 2011 on February 22, 2010, at a price equal to 100.5% of the principal amount of the notes plus accrued and unpaid interest to the redemption date. The notice of redemption was sent to the holders of the outstandi...  January 05, 2010 Incyte to Present at the 28th Annual JPMorgan Healthcare Conference WILMINGTON, Del., Jan 05, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 28th Annual JPMorgan Healthcare Conference on Tuesday, January 12, 2010 at 9:30 a.m. PT / 12:30 p.m. ET. Presenting for Incyte Corporation will be Paul Friedman, M.D., president and chief executive officer. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A repla...  December 21, 2009 Incyte to Host Conference Call to Discuss Its Collaboration with Lilly for the Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies Conference Call Scheduled Today at 8:30 a.m. ETWILMINGTON, Del., Dec 21, 2009 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a conference call for 8:30 a.m. ET on Monday, December 21, 2009. Conference Call: December 21, 2009 at 8:30 a.m. ET Domestic Dial In Number: 877-407-8037 International Dial In Number: 201-689-8037 Conference ID # 340419 If you are unable to participate, a replay of the conference call will be available for thirty d...

Download the Incyte 2008 Shareholder Letter (87.7KB PDF). Click here to view our 10-K.

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Investor Tool Kit

	Print Page
	E-mail Page
	RSS Feeds
	E-mail Alerts
	Financial Tear Sheet

Investor Contact

Pamela M. Murphy VP, Investor Relations and Corporate Communications Experimental Station Route 141 & Henry Clay Road Building E336 Wilmington, DE 19880 302.498.6944 302.425.2707 pmurphy@incyte.com